JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.43 CNY | -0.96% |
|
-2.43% | -42.27% |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.02B 14.67B |
|---|---|---|---|---|---|
| Net income 2024 * | 329M 2.38B | Net income 2025 * | 413M 2.99B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
6.15
x | P/E ratio 2025 * |
4.9
x | Employees | 451 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 23.92% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.96% | ||
| 1 week | -2.43% | ||
| Current month | -12.56% | ||
| 1 month | -15.48% | ||
| 3 months | -26.68% | ||
| 6 months | -42.77% | ||
| Current year | -42.27% |
1 week
15.95
16.86
1 month
15.9319.40
Current year
15.0128.65
1 year
15.0152.41
3 years
15.0179.42
5 years
15.0179.42
10 years
15.0179.42
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Hui Zhang
CEO | Chief Executive Officer | 66 | 23-10-26 |
Qiang Huang
DFI | Director of Finance/CFO | 44 | 21-03-31 |
Jun Yu
CHM | Chairman | 55 | 15-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rong Shao
BRD | Director/Board Member | 62 | 20-06-14 |
Liang Bin Zhang
BRD | Director/Board Member | 49 | 15-05-31 |
Jian Qiang Guan
BRD | Director/Board Member | 62 | 20-06-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 16.43 | -0.96% | 490,015 |
| 24-04-23 | 16.59 | +0.61% | 428,047 |
| 24-04-22 | 16.49 | +0.12% | 564,988 |
| 24-04-19 | 16.47 | -1.55% | 558,989 |
| 24-04-18 | 16.73 | -0.65% | 528,569 |
End-of-day quote Shanghai S.E., April 23, 2024
More quotes
Jiangsu gdk Biotechnology Co Ltd is a biopharmaceutical company engaged in the research, development, production, and sales of human vaccines. The Companyâs main product is a tetravalent influenza virus split vaccine, which is mainly used to prevent influenza caused by two influenza A virus strains and two influenza B virus strains. The Company's research products also include a variety of human vaccines for the prevention of epidemic colds, rabies, chickenpox, shingles, and pneumonia. The Company distributes its service within the domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
16.43
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -42.27% | 282M | |
| -2.86% | 87.37B | |
| +3.95% | 41.01B | |
| -21.94% | 28.08B | |
| +53.11% | 24.72B | |
| -5.41% | 17.47B | |
| -44.23% | 11.69B | |
| -17.60% | 11.6B | |
| -13.96% | 11.56B | |
| -0.22% | 8.44B |
- Stock Market
- Equities
- 688670 Stock
